142 related articles for article (PubMed ID: 30943161)
1. [The organization of pharmacovigilance in France, in Europe and worldwide - From label to delivery of an innovative treatment: what a journey! (3)].
Lebrun-Vignes B
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():37-39. PubMed ID: 30943161
[No Abstract] [Full Text] [Related]
2. [An institutional point of view - From label to delivery of an innovative treatment: what a journey! (4)].
Belcastro J
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():39-41. PubMed ID: 30943162
[No Abstract] [Full Text] [Related]
3. [Anticipating changes and risks in adults - From label to delivery of an innovative treatment: what a journey! (2)].
Antoine JC
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():35-36. PubMed ID: 30943160
[No Abstract] [Full Text] [Related]
4. [Experiences and reflections in the paediatric context - From label to delivery of an innovative treatment: what a journey! (1)].
Cancès C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():32-34. PubMed ID: 30943159
[No Abstract] [Full Text] [Related]
5. Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives.
Jose J; Rafeek NR
Ther Innov Regul Sci; 2019 Nov; 53(6):781-786. PubMed ID: 30554527
[TBL] [Abstract][Full Text] [Related]
6. [Opinion survey of European pharmacovigilance: opinion of French practitioners].
Pierfitte C; Hanesse B; Royer RJ
Therapie; 1995; 50(2):171-2. PubMed ID: 7631296
[No Abstract] [Full Text] [Related]
7. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
8. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
Biron P; Balency D
Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
[TBL] [Abstract][Full Text] [Related]
9. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
Montastruc JL
Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
[No Abstract] [Full Text] [Related]
10. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
11. French pharmacovigilance: Missions, organization and perspectives.
Vial T
Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
[TBL] [Abstract][Full Text] [Related]
12. [Health technology assessment in the field of rare diseases at Haute Autorité de Santé in France].
Bélorgey C
Med Sci (Paris); 2018 May; 34 Hors série n°1():49-50. PubMed ID: 29911564
[No Abstract] [Full Text] [Related]
13. Adaptive licensing - A way forward in the approval process of new therapeutic agents in Europe.
Rosano GMC; Anker SD; Marrocco W; Coats AJS
Int J Cardiol; 2015 Apr; 184():568-569. PubMed ID: 25767018
[No Abstract] [Full Text] [Related]
14. [Which follow-up for innovative treatments?].
Campana-Salort E; Espil-Taris C; Prigent H; de Antonio M; Lebrun-Vignes B; Tiffreau V; Honnet G
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():54-56. PubMed ID: 30943166
[No Abstract] [Full Text] [Related]
15. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
16. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.
Oliveira JL; Lopes P; Nunes T; Campos D; Boyer S; Ahlberg E; van Mulligen EM; Kors JA; Singh B; Furlong LI; Sanz F; Bauer-Mehren A; Carrascosa MC; Mestres J; Avillach P; Diallo G; Díaz Acedo C; van der Lei J
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):459-67. PubMed ID: 23208789
[TBL] [Abstract][Full Text] [Related]
17. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
[TBL] [Abstract][Full Text] [Related]
18. Medicine Safety Monitoring in Pediatric Population in India.
Kaur I; Kalaiselvan V; Singh GN
Indian J Pediatr; 2016 May; 83(5):479-80. PubMed ID: 26634262
[No Abstract] [Full Text] [Related]
19. [The French pharmacovigilance system: structure and missions].
Welsch M; Alt M; Richard MH; Imbs JL
Presse Med; 2000 Jan; 29(2):102-6. PubMed ID: 10682040
[TBL] [Abstract][Full Text] [Related]
20. Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database.
Khouri C; Revol B; Lepelley M; Mallaret M; Cracowski JL
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1427-1428. PubMed ID: 30379373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
